

Charcot Marie Tooth Disease. A Single Disorder?

Michel Fontes

► **To cite this version:**

Michel Fontes. Charcot Marie Tooth Disease. A Single Disorder?. International Journal of Molecular Sciences, MDPI, 2018, 19 (12), pp.3807. 10.3390/ijms19123807 . hal-02067479

HAL Id: hal-02067479

<https://hal-amu.archives-ouvertes.fr/hal-02067479>

Submitted on 9 Dec 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.





Editorial

Charcot Marie Tooth Disease. A Single Disorder?

Michel Fontés

C2VN, Aix Marseille Université, INRA 1260—INSERM 1263, 13007 Marseille, France;
michel.fontes@univ-amu.fr; Tel.: 33-491-32-443

Received: 23 November 2018; Accepted: 26 November 2018; Published: 29 November 2018



1. Introduction

Peripheral neuropathies are subdivided into acquired and hereditary transmitted disorders. Among hereditary peripheral neuropathies, the most frequent is Charcot-Marie-Tooth disease (CMT). We will describe below, in detail, this disorder and its different forms.

Charcot-Marie-Tooth disease constitutes a clinically and genetically heterogeneous group of hereditary motor and sensory peripheral neuropathies. On the basis of electrophysiologic properties and histopathology, CMT has been divided into primary peripheral demyelinating (type 1) and primary peripheral axonal (type 2) neuropathies. The demyelinating neuropathies classified as CMT type 1, also known as HMSN I, are characterized by severely reduced motor nerve conduction velocities (NCV) (less than 38 m/s) and segmental demyelination and remyelination with onion bulb formations on nerve biopsy. The axonal neuropathies classified as CMT type 2, also known as HMSN II, are characterized by normal or mildly reduced NCVs and chronic axonal degeneration and regeneration on nerve biopsy. Among the CMT1 group, there are X-linked, autosomal dominant and autosomal recessive forms of CMT.

The typical presenting symptom is a weakness of the feet and ankles. The initial physical findings are depressed or absent tendon reflexes with a weakness of foot dorsiflexion at the ankle. The typical affected adult has a bilateral foot drop, symmetrical atrophy of muscles below the knee (stork leg appearance), pes cavus, atrophy of intrinsic hand muscles, especially the thenar muscles of the thumb, and absent tendon reflexes in both upper and lower extremities. The life span is not decreased [1].

2. Prevalence of CMT (Charcot-Marie-Tooth) Subtypes

There are only a few epidemiologic studies on the prevalence of CMT disease. The most generally accepted is the study by Skre published in 1974 [2]. A major reason is probably the heterogeneity of this disorder. Actually, about 80 genes presenting mutations and a CMT phenotype have been recorded. Therefore, the CMT phenotype is not homogenous and could be defined in a general term: “hereditary peripheral neuropathies”, whatever the cause is. We will describe below, the estimated prevalence of the CMTX1, a specific form of CMT disease.

CMT is also known as hereditary motor and sensory neuropathy (HMSN). Hereditary motor neuropathy (HMN) and hereditary sensory neuropathy (HSN) are related disorders and can also be considered as part of the CMT family. The most reliable evaluation of CMT prevalence is one affected person in 2500 [2]. Over 80 causative genes of CMT have been identified and many more remain unknown. The natural history of these various forms of CMT remains poorly understood, at least in part, because these are rare disorders and individual centers do not follow enough patients to perform natural history studies. Furthermore, validated clinical instruments for measuring disease severity have become available only recently and have not yet been employed in many of the rare CMT subtypes. The Inherited Neuropathies Consortium (INC) is a member of the Rare Diseases Clinical Research Network (RDCRN) and was created in part to perform natural history studies in CMT. Quantifiable clinical data add to the literature in providing the clinical severity of a variety of

CMT subtypes and also act as a baseline for a longitudinal natural history study of CMT subtypes, a prerequisite for clinical trials.

From a recent study of the consortium published in 2015 [3], the frequency of different CMT subtypes ranged from 62% of patients with a genetic diagnosis for the most frequent subtype (CMT1A) up to 0.1% for CMT1D.

3. Different Genes, Different Proteins, Different Functions

Mutations in more than 80 different genes cause CMT. Below are listed the genes of known functions that could be regrouped in different sections:

3.1. Genes Involved in Cell Division

PMP22, the gene involved in CMT1A, was first identified as Gas3 in a screen of genes involved in growth arrest [4]. Histological analysis demonstrated that CMT1A is frequently associated with an abnormal number of Schwann cells (SC) between two Ranvier nodes (normally only one). This indicates that anomalies in the PMP22 expression have an impact in the growth arrest of Schwann cells [5–7]. Exploration of the cellular and rodent animal models showed that anomalies of myelination occurred in early phases of SC differentiation when the myelination of axons starts [8,9]. This indicates that anomalies of growth arrest impair SC terminal differentiation [10]. This is strengthened by observations that anomalies in nerve conduction velocity in youths, before full myelination and clinical signs appeared.

Another example regards mutations in Gjb1 (a gene coding for Connexin 32 CX32) that are involved in CMTX1 phenotype. A screen for genes potentially involved in the stability of mitoses, as well as observations in a mouse model or in cells from CMTX1 patients, demonstrated that Cx32 is involved in mitotic stability [11].

3.2. tRNA Synthetases

Aminoacyl-tRNA synthetases (ARSs) are ubiquitously expressed enzymes responsible for charging tRNAs with their cognate amino acids, therefore they essential for the first step in protein synthesis. Mutations in the majority of the 37 nuclear-encoded human ARS genes have been linked to a variety of recessive and dominant tissue-specific disorders. Current data indicate that impaired enzyme function could explain the pathogenicity, however not all pathogenic ARSs mutations result in deficient catalytic function; thus, the consequences of mutations may arise from other molecular mechanisms.

The peripheral nerves are frequently affected, as illustrated by the high number of mutations in tRNA synthetases causing Charcot-Marie-Tooth disease (CMT) but it remains particularly unclear what the cause of the high degree of tissue specificity could be. Various noncanonical functions of ARSs have become increasingly interesting. Understanding why peripheral nerves are predominantly affected will open potential therapeutic targets for a larger group of CMT patients; however, further research is still needed. For a review see Reference [12].

3.3. Mitochondrial Genes

Mitochondrial dysfunction plays a relevant role in the pathogenesis of neurological and neuromuscular diseases. Mitochondria may be involved as a primary defect of either the mtDNA or nuclear genome encoded subunits of the respiratory chain. Inherited peripheral neuropathies are frequently associated with abnormal mitochondrial network dynamics. As an example, mutations in the MFN2 gene cause the most frequent form of the autosomal dominant axonal Charcot-Marie-Tooth disease, CMT2A [13]. MFN2 is a GTPase involved in mitochondrial fusion processes [14,15]. Moreover, GDAP1 has been recently related to the mitochondrial fission in mammalian cells [16] and, interestingly, mutations in the GDAP1 gene are the cause of the most common form of autosomal recessive CMT, either axonal or demyelinating [17,18]. This gene encodes a member of the ganglioside-induced differentiation-associated protein family, which may play a role in a signal transduction pathway

during neuronal development. These and other disorders are the most recent instances of diseases related to mitochondrial abnormal motility, fusion, and fission. The pathomechanisms underlying these disorders probably include a complex relationship between mitochondrial dynamics and transport across the axon. However, although biochemical functions are different, mutations in these genes result in anomalies in mitochondrial dynamics.

3.4. Myelin Compaction

Mutations in Myelin Protein Zero (MPZ) cause Charcot-Marie-Tooth type 1B [18]. Myelin protein zero (P0) is a membrane glycoprotein encoded by the MPZ gene. P0 is a major structural component of the myelin sheath in the peripheral nervous system (PNS) that accounts for over 50% of all proteins in the peripheral nervous system, making it the most common protein expressed in the PNS.

Myelin protein zero consists of an extracellular N-terminal domain, a single transmembrane region, and a smaller positively charged intracellular region. Its cytoplasmic domain is highly positively charged but presumably does not fold into a globular structure. The extracellular domain is structurally similar to the immunoglobulin domain and therefore the protein is considered as belonging to the immunoglobulin superfamily.

It is postulated that myelin protein zero is a structural element in the formation and stabilization of peripheral nerve myelin [19,20]. Myelin protein zero is also hypothesized to serve as a cell adhesion molecule, holding multiple layers of myelin together. When a myelinating cell wraps its membrane around an axon multiple times, generating multiple layers of myelin, myelin protein zero helps keep these sheets compact. It does so by holding its characteristic coil structure together by the electrostatic interactions of its positively charged intracellular domain with acidic lipids in the cytoplasmic face of the opposite bilayer and by the interaction between hydrophobic globular 'heads' of adjacent extracellular domains. Most patients with the CMT1B present in two phenotypic groups: one with extremely slow nerve conduction velocities and the onset of symptoms during the period of motor development; and a second with normal or near normal nerve conduction velocities and the onset of symptoms in adults.

3.5. Transcription Factors

Mutations affecting two transcription factors, EGR2/Krox20 [21] and Sox10 [22], have been found in CMT. EGR2/Krox20 is a zinc finger-containing protein and null mutant mice for this protein do not develop peripheral nerve myelin. This is consistent with several recent studies suggesting a broad function of EGR2/Krox20 in the regulation of Schwann-cell myelination by controlling myelin protein gene expression [23] and cholesterol/lipid biosynthesis via the sterol regulatory element binding protein (SREBP) pathway. EGR2/Krox20 mutations in humans are associated with demyelinating or dysmyelinated forms of CMT (CMT1D, CMT4E). Mutations in the zinc finger domain lead to the dominantly inherited form CMT1D. A particular mutation, located in the R1 domain of EGR2/Krox20, accounts for CMT4E.

4. Implications in Therapeutical Development

In line of the preceding chapter, cellular, biochemical and molecular phenotypes are different in CMT subtypes, caused by mutations in different genes. This asks the question of developing a drug that could cure all forms of CMT. Therefore, two lines of approaches could be proposed regarding drug development in a specific CMT subtype.

The first possibility is to develop a strategy able to correct the direct consequences of the biochemical/molecular anomaly causing the disorder. This could be achieved using different techniques: small molecules (drugs) treatment, gene therapy, specific antisense, etc. This has been proposed for the CMT1A [24–26], CMTX1 [27–29], and CMT1B [30] subtypes.

The second possibility is to target the downstream consequences of mutations in a specific gene. For example, different CMT subtypes have been associated with the inflammation of peripheral

nerves. As a consequence, a therapeutical strategy has been proposed to treat inflammation and, as a consequence, to stop myelin degradation [31]. However, this option is probably limited to demyelinating CMT subtypes, as these disorders only present neuroinflammation.

Finally, a promising approach will be to develop rehabilitation programs specifically adapted to CMT patients [32]. This aspect has been neglected in the past and should probably be developed.

Funding: This research received no external funding.

Conflicts of Interest: The author declare no conflict of interest.

References

1. Pareyson, D.; Saveri, P.; Pisciotta, C. New developments in Charcot-Marie-Tooth neuropathy and related diseases. *Curr. Opin. Neurol.* **2017**, *30*, 471–480. [[CrossRef](#)] [[PubMed](#)]
2. Skre, H. Genetic and clinical aspects of Charcot-Marie-Tooth disease. *Clin. Genet.* **1974**, *6*, 98–118. [[CrossRef](#)] [[PubMed](#)]
3. Fridman, V. The international CMT consortium. *J. Neurol. Neurosurg. Psychiatry* **2015**, *86*, 873–878. [[CrossRef](#)] [[PubMed](#)]
4. Manfioletti, G.; Ruaro, M.E.; Del Sal, G.; Philipson, L.; Schneider, C. A growth arrest-specific (gas) gene codes for a membrane protein. *Mol. Cell Biol.* **1990**, *10*, 2924–2930. [[CrossRef](#)] [[PubMed](#)]
5. Sancho, S.; Young, P.; Suter, U. Regulation of Schwann cell proliferation and apoptosis in PMP22-deficient mice and mouse models of Charcot-Marie-Tooth disease type 1A. *Brain* **2001**, *124* (Pt 11), 2177–2187. [[CrossRef](#)] [[PubMed](#)]
6. Brancolini, C.; Edomi, P.; Marzinotto, S.; Schneider, C. Exposure at the cell surface is required for gas3/PMP22 to regulate both cell death and cell spreading: Implication for the Charcot-Marie-Tooth type 1A and Dejerine-Sottas diseases. *Mol. Biol. Cell* **2000**, *11*, 2901–2914. [[CrossRef](#)] [[PubMed](#)]
7. Fabbretti, E.; Edomi, P.; Brancolini, C.; Schneider, C. Apoptotic phenotype induced by overexpression of wild-type gas3/PMP22: Its relation to the demyelinating peripheral neuropathy CMT1A. *Gene. Dev.* **1995**, *9*, 1846–1856. [[CrossRef](#)] [[PubMed](#)]
8. Huxley, C.; Passage, E.; Manson, A.; Putzu, D.; Figarella-Branger, J.F.; Pellissier, M. Construction of a mouse model of Charcot-Marie-Tooth disease type 1A by pronuclear injection of human YAC DNA. *Hum. Mol. Genet.* **1996**, *5*, 563–569. [[CrossRef](#)] [[PubMed](#)]
9. Sereda, M.; Griffiths, I.; Puhlhofer, A.; Stewart, H.; Rossner, M.J.; Zimmerman, F.; Magyar, J.P.; Schneider, A.; Hund, E.; Meinck, H.M.; et al. A rat transgenic model for Charcot-Marie-Tooth disease. *Neuron* **1996**, *16*, 1049–1060. [[CrossRef](#)]
10. Magyar, J.P.; Martini, R.; Ruelicke, T.; Aguzzi, A.; Adlkofer, K.; Dembic, Z.; Zielasek, J.; Toyka, K.V.; Suter, U. Impaired differentiation of Schwann cells in transgenic mice with increased PMP22 gene dosage. *J. Neurosci.* **1996**, *16*, 5351–5360. [[CrossRef](#)] [[PubMed](#)]
11. Mones, S.; Bordignon, B.; Fontés, M. Connexin 32 is involved in mitosis. *Glia* **2012**, *60*, 457–464. [[CrossRef](#)] [[PubMed](#)]
12. Boczonadi, V.; Jennings, M.J.; Horvath, R. The role of tRNA synthetases in neurological and neuromuscular disorders. *FEBS Lett.* **2018**, *592*, 703–717. [[CrossRef](#)] [[PubMed](#)]
13. Züchner, S.; Mersyanova, I.V.; Muglia, M.; Bissar-Tadmouri, N.; Rochelle, J.; Dadali, E.L.; Zappia, M.; Nelis, E.; Patitucci, A.; Senderek, J.; et al. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. *Nat. Genet.* **2004**, *36*, 449–451. [[CrossRef](#)] [[PubMed](#)]
14. Chen, H.; Detmer, S.A.; Ewald, A.J.; Griffin, E.E.; Fraser, S.E.; Chan, D.C. Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. *J. Cell Biol.* **2003**, *160*, 189–200. [[CrossRef](#)] [[PubMed](#)]
15. Chen, H.; Chomyn, A.; Chan, D.C. Disruption of fusion results in mitochondrial heterogeneity and dysfunction. *J. Biol. Chem.* **2005**, *280*, 26185–26192. [[CrossRef](#)] [[PubMed](#)]
16. Niemann, A.; Rueegg, M.; La Padula, V.; Schenone, A.; Suter, U. Ganglioside-induced differentiation associated protein 1 (GDAP1) is a regulator of the mitochondrial network—New implications for Charcot-Marie-Tooth disease. *J. Cell Biol.* **2005**, *170*, 1067–1078. [[CrossRef](#)] [[PubMed](#)]

17. Cuesta, A.; Pedrola, L.; Sevilla, T.; García-Planells, J.; Chumillas, M.J.; Mayordomo, F.; LeGuern, E.; Marín, I.; Vílchez, J.J.; Palau, F. The gene encoding ganglioside-induced differentiation associated protein 1 is mutated in axonal Charcot-Marie-Tooth type 4A disease. *Nat. Genet.* **2002**, *30*, 22–25. [[CrossRef](#)] [[PubMed](#)]
18. Baxter, R.V.; Ben Othmane, K.; Rochelle, J.M.; Stajich, J.E.; Hulette, C.; Dew-Knight, S.; Hentati, F.; Ben Hamida, M.; Bel, S.; Stenger, J.E.; et al. Ganglioside-induced differentiation associated protein-1 is mutant in Charcot-Marie-Tooth disease type 4A/8q21. *Nat. Genet.* **2002**, *30*, 21–22. [[CrossRef](#)] [[PubMed](#)]
19. Giese, K.P.; Martini, R.; Lemke, G.; Soriano, P.; Schachner, M. Mouse P0 gene disruption leads to hypomyelination, abnormal expression of recognition molecules, and degeneration of myelin and axons. *Cell* **1992**, *71*, 565–576. [[CrossRef](#)]
20. Martini, R.; Zielasek, J.; Toyka, K.V.; Giese, K.P.; Schachner, M. Protein zero (P0)-deficient mice show myelin degeneration in peripheral nerves characteristic of inherited human neuropathies. *Nat. Genet.* **1995**, *11*, 281–286. [[CrossRef](#)] [[PubMed](#)]
21. Warner, L.E.; Mancias, P.; Butler, I.J.; McDonald, C.M.; Keppen, L.; Koob, K.G.; Lupski, J.R. Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies. *Nat. Genet.* **1998**, *18*, 382–384. [[CrossRef](#)] [[PubMed](#)]
22. Britsch, S.; Goerich, D.E.; Riethmacher, D. The transcription factor Sox10 is a key regulator of peripheral glial development. *Genes Dev.* **2001**, *15*, 66–78. [[CrossRef](#)] [[PubMed](#)]
23. Topilko, P.; Schneider-Maunoury, S.; Levi, G.; Baron-Van Evercooren, A.; Chennoufi, A.B.; Seitanidou, T.; Babinet, C.; Charnay, P. Krox-20 controls myelination in the peripheral nervous system. *Nature* **1994**, *371*, 796–799. [[CrossRef](#)] [[PubMed](#)]
24. Passage, E.; Norreel, J.C.; Noack-Fraissignes, P.; Sanguedolce, V.; Pizant, J.; Thirion, X.; Robaglia-Schlupp, A.; Pellissier, J.F.; Fontés, M. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. *Nat. Med.* **2004**, *10*, 396–401. [[CrossRef](#)] [[PubMed](#)]
25. Sereda, M.W.; Meyer zu Hörste, G.; Suter, U.; Uzma, N.; Nave, K.A. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). *Nat. Med.* **2003**, *9*, 1533–1537. [[CrossRef](#)] [[PubMed](#)]
26. Zhao, H.T.; Damle, S.; Ikeda-Lee, K.; Kuntz, S.; Li, J.; Mohan, A.; Kim, A.; Hung, G.; Scheideler, M.A.; Scherer, S.S.; et al. PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models. *J. Clin. Invest.* **2018**, *128*, 359–368. [[CrossRef](#)] [[PubMed](#)]
27. Mones, S.; Bordignon, B.; Peiretti, F.; Landrier, J.F.; Gess, B.; Bourguignon, J.J.; Bihel, F.; Fontés, M. CamKII inhibitors reduce mitotic instability, connexon anomalies and progression of the *in vivo* behavioral phenotype in transgenic animals expressing a mutated Gjb1 gene. *Front Neurosci.* **2014**, *13*, 8–151.
28. Mones, S.; Gess, B.; Bordignon, B.; Altié, A.; Young, P.; Bihel, F.; Fraternali, M.; Peiretti, F.; Fontes, M. CMTX11 patients' cells present genomic instability corrected by CamKII inhibitors. *Orphanet J. Rare Dis.* **2015**, *10*, 56. [[PubMed](#)]
29. Kagiava, A.; Karaiskos, C.; Richter, J.; Tryfonos, C.; Lapathitis, G.; Sargiannidou, I.; Christodoulou, C.; Kleopa, K.A. Intrathecal gene therapy in mouse models expressing CMT1X mutations. *Hum. Mol. Genet.* **2018**, *27*, 1460–1473. [[CrossRef](#)] [[PubMed](#)]
30. Das, I.; Krzyzosiak, A.; Schneider, K.; Wrabetz, L.; D'Antonio, M.; Barry, N.; Sigurdardottir, A.; Bertolotti, A. Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory subunit. *Science* **2015**, *348*, 239–242. [[CrossRef](#)] [[PubMed](#)]
31. Groh, J.; Martini, R. Neuroinflammation as modifier of genetically caused neurological disorders of the central nervous system: Understanding pathogenesis and chances for treatment. *Glia* **2017**, *65*, 1407–1422. [[CrossRef](#)] [[PubMed](#)]
32. Corrado, B.; Ciardi, G.; Bargigli, C. Rehabilitation Management of the Charcot-Marie-Tooth Syndrome: A Systematic Review of the Literature. *Medicine* **2016**, *95*, e3278. [[CrossRef](#)] [[PubMed](#)]

